• Police seek suspects in deadly birthday party shooting
  • Lawmakers launch inquires into U.S. boat strike
  • Nov. 29, 2025, 10:07 PM EST / Updated Nov. 30, 2025,…
  • Mark Kelly says troops ‘can tell’ what orders…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

Nov. 28, 2025, 6:00 PM ESTBy Freddie Clayton and Fiona DayThe rolling plains of Kenya’s Maasai Mara and the millions of animals that live there face a shiny new intrusion: a gleaming Ritz-Carlton safari camp.With private plunge pools, butler service and panoramic views commanding more than $5,000 a night, the 20-hectare lodge has become a luxury lightning rod for controversy.Leaders of the Maasai — an ethnic group of traditionally nomadic herders with ancestral ties to the area — and conservationists warn the new tourist destination threatens a migration corridor vital to the movement of vast numbers of animals and have filed a lawsuit to halt its operations.What’s at stake, they argue, is not just a new lodge, but the accelerating pressures of tourism on wildlife, biodiversity and the very spectacle that draws these tourists in the first place. The camp opened on Aug. 15 during the height of the Great Migration, where millions of wildebeest, zebras and other grazing animals move back and forth between the Serengeti plains in Tanzania and the Maasai Mara National Reserve (MMNR) in Kenya, a process that researchers say allows animals to find food and water and maintain genetic diversity among herds.The Ritz-Carlton, Masai Mara Safari Camp. The rapid growth in lodges and camps has sometimes clashed with conservation efforts.Jiri Lizler / Marriott InternationalTourists have long flocked to the savannah by the hundreds of thousands, hoping to witness one of the largest movements of mammals in the world, as herds cross rivers and plains teeming with predators.But the new camp, which boasts “front-row seats to one of the world’s greatest natural wonders” on its website, may threaten the migration that visitors come to witness, conservations and Maasai leaders say. The Ritz-Carlton camp, on a bend in the Sand River, sits on “one of the most favored corridors for these animals,” Maasai elder Meitamei Olol Dapash told NBC News in an interview Sunday.“Any guide will tell you, that is the crossing they use,” said Dapash, who filed a lawsuit in August in a Kenyan court against Ritz-Carlton’s owner, Marriott International, the world’s largest hotel chain, as well as the project’s local owner and operator, Lazizi Mara Limited, and Kenyan authorities.Dapash, executive director of the Institute for Maasai Education, Research and Conservation (MERC), who has a PhD in Sustainability Education from Prescott College in Arizona, alleges in the lawsuit that the 20-suite camp obstructs the crucial migration corridor and is asking the court to restore the land to its original condition.He told NBC News in an interview there had been instances of wildebeest turning back to avoid the camp and that an elephant was seen struggling to find a path across the river after using the location for more than a decade.Female lions with cubs in Masai Mara, Kenya.Henrik Karlsson / Getty Images file“Attachment to the land and to the wildlife exists up to this very day,” Dapash said, adding that the Maasai had seen populations dwindling. The new camp, he added, “was the last straw for us, we just didn’t want to let this happen.”The Kenya Wildlife Service government agency pushed back at claims the lodge has impacted wildebeest migration, citing monitoring data that it says shows it does not “fall within, obstruct, or interfere with any wildebeest migration corridors” and adding that migrating wildebeest “are using the entire breadth of the Kenya-Tanzania border.”It said that “all ecological, environmental and regulatory requirements were thoroughly met and validated.”Marriott International told NBC News that the development underwent an environmental impact assessment (EIA) “in full compliance with” Kenya’s environmental protections.The company said it is committed to “the principles of responsible tourism” but declined to comment on Dapash’s claims that the Ritz-Carlton blocked a key route for local wildlife or its own steps to mitigate the construction’s impact, saying these were matters for Narok County, which manages the reserve on the Maasai’s behalf.Narok County did not respond to NBC News’ request for comment. In court documents seen by NBC News, the county claims that the safari camp complies with the Maasai Mara Management Plan, which imposes a moratorium on new developments amid concerns that poorly regulated tourism was stifling wildlife migration and threatening the reserve’s ecosystem.Lazizi Mara Limited said the moratorium is part of the case before the court, adding: “We wouldn’t want to comment on issues that are pending determination.”Dapash told NBC News that he had “no issue with business, but this is not just about hotel, it is about the long-term survival of the game reserve.” “We feel like we are losing the land, we are losing the wildlife,” he said.The lawsuit comes amid mounting concerns about the health of the 580-square-mile reserve, where tourist numbers have nearly tripled in recent decades. The Maasai Mara National Reserve reported over 300,000 tourists in 2023. In 1980, total visitor entry was 114,000. Tourism in the Mara generates an estimated $20 million annually and thousands more indirectly, according to the reserve. In 2023, tourism across the country contributed around 7% of Kenya’s gross domestic product, according to the World Travel and Tourism Council.But the rapid growth in lodges and camps has sometimes clashed with conservation efforts. “A hotel is never just a hotel,” Dr. Chloe Buiting, a vet and wildlife researcher working in the Maasai Mara, said in an interview. “It’s infrastructure, it’s roads, it’s changes to the water and the resources and the use of land.”Seasonal variation in the availability and quality of food forces animals to move around, said Joseph Ogutu, a Kenyan researcher at the University of Hohenheim in Germany. But he said developments like the Ritz-Carlton are having “a negative effect on migration, because most of these facilities are close to rivers where animals either drink water or breed or seek refuge.”Dapash’s cause has also found support among experts and tourism groups.Grant Hopcraft, a professor of conservation ecology at the University of Glasgow, who has been collaring migratory wildebeest in the Serengeti-Mara since 1999, presented maps and data to the court in October showing “regular cross-border movement of wildebeest” at the location of the lodge, according to his affidavit.RIDE International, a U.S.-based nonprofit providing cultural exchanges and immersive tours in East Africa, has also thrown its support behind Dapash’s lawsuit.The Mara has been suffering for a long time, said Riley Jon Blackwell, the company’s executive director, with “large hotel chains coming in and trying to service the luxury guests who command to see the best of the best for wildlife.”The Ritz-Carlton safari camp was “not surprising,” he added in an interview. “It’s just kind of a culmination of a long time, of a direction of things leading this way.”The camp holds a 2.2-star rating on Google Reviews, with many posters criticizing its environmental impact. Others have praised their stay at the park. A court is scheduled to hear the case in December.If Dapash is successful with his lawsuit, Buiting said it could “set a very interesting precedent” for future developments in the reserve.“From a legal perspective, this could actually be groundbreaking, a turning point,” she added.Freddie ClaytonFreddie Clayton is a freelance journalist based in London. Fiona DayFiona Day is a social news editor for NBC News based in London.Reuters contributed.

admin - Latest News - November 28, 2025
admin
5 views 15 secs 0 Comments




The rolling plains of Kenya’s Maasai Mara and the millions of animals that live there face a shiny new intrusion: a gleaming Ritz-Carlton safari camp



Source link

TAGS:
PREVIOUS
Trump 'cancelling' Biden orders signed by autopen
NEXT
Trump 'cancelling' Biden orders signed by autopen
Related Post
November 13, 2025
Cowboys set up fund for Kneeland’s pregnant girlfriend
November 14, 2025
DHS announces $10K bonuses for 'exemplary' TSA agents
October 15, 2025
Aid trucks arrive in southern Gaza
November 7, 2025
Nov. 7, 2025, 5:55 PM ESTBy Berkeley Lovelace Jr.President Donald Trump hailed his deal to slash the price of blockbuster weight loss drugs as a game changer, promising to make Wegovy and Zepbound more affordable for millions of Americans. But major gaps in the plan could blunt its impact, drug policy experts say: Some of the drugs the administration has promised discounts on haven’t been approved yet by the Food and Drug Administration; the lower prices for people paying out of pocket only appear to apply to the lowest doses of the drugs; and the deal doesn’t expand Medicare coverage to people seeking treatment for weight loss alone.“It’s a situation where we have more questions than answers,” said Juliette Cubanski, deputy director of the Medicare policy program at KFF, a nonpartisan health policy research group. “Based on what we didn’t hear, that suggests to me that there’s a lot that the administration itself hasn’t even ironed out as of yet.”“It just feels,” she added, “a little bit too squishy right now.”U.S. President Donald Trump, joined by members of the pharmaceutical industry and administration officials, delivers remarks on lowering drug prices in the Oval Office at the White House on November 06, 2025 in Washington, DC. Andrew Harnik / Getty ImagesThe announcement marks one of the most ambitious efforts yet to tackle the high cost of weight loss drugs in the U.S. Wegovy and Zepbound carry list prices above $1,000 a month, a cost that both Republicans and Democrats have criticized as far too high, especially compared with what other countries pay. Administration officials say there’s still time to iron out details before the lower prices take effect. The lower prices that will be available through the administration’s self-pay platform, TrumpRx, aren’t expected to go live until the end of the year, and the Medicare and Medicaid changes won’t roll out until mid-2026.“I think the administration deserves credit for continuing to try to push the envelope on finding ways to lower prescription drug prices in the U.S.,” Cubanski said. She said KFF polling shows that health care costs, including prescription drugs, are a top concern for Americans.Art Caplan, the head of the division of medical ethics at NYU Grossman School of Medicine in New York City, said the deal, while ambitious, lacks crucial details.“It’s just murky as to how this will take shape, how the programs will work,” Caplan said. “You can’t really tell from what’s going on.”Unapproved drugsSeveral forms of the drugs included in the deal haven’t yet received FDA approval. That includes oral versions of the weight loss drugs — which are still under development or FDA review — and Eli Lilly’s new multidose injection pens, which haven’t been approved but the drugmaker says are the versions included in the pricing agreement.Lawrence Gostin, director of the O’Neill Institute for National and Global Health Law at Georgetown University, said that makes the administration’s promises premature, since those lower prices can’t take effect until the products are on the market. “It is reckless to negotiate pricing deals on products which the FDA have not yet approved as safe and effective,” Gostin said. “The administration is getting way out ahead of its own safety agency.”An oral version of Wegovy, from Novo Nordisk, is being reviewed by the FDA. A decision is expected in the coming weeks. A multidose version of Zepbound is under review by the FDA, Lilly said. The company hasn’t submitted its weight loss pill, orforglipron, to the agency yet. Lilly CEO David Ricks told NBC News’ Tom Llamas on “Top Story” that the FDA would review the pill quickly. “As part of the deal, they’ve agreed to give us an expedited approval,” Ricks said. Different doses, different pricesThe White House said that both the pills and the injection pens will be available for discounted prices for people who pay out of pocket. Starting doses of weight loss pills will cost $149 for a month’s supply, and the shots will cost an average of $350 for a month’s supply, the White House said. The price of the injections is expected to fall to about $250 within two years, it said.But people may end up paying more.When people start on a weight loss drug, they start with the lowest dose possible — the starting dose — to allow the body to get used to the drug. Over the course of several months, however, they increase the dose until they get to a dose that’s effective for weight loss. Wegovy comes in five doses and Zepbound comes in six, with the most weight loss seen at the highest doses. Administration officials said the starting doses of GLP-1 pills will cost $149 a month, but did not say what higher doses would be.For the injections, the exact White House language was vague: The shots will initially have a “weighted average” price of $350 a month. Lilly, however, said Zepbound will be available at the lowest dose for $299 a month, with additional doses priced up to $449. A spokesperson for Novo Nordisk didn’t say whether doses would have different prices, but said it plans to publish an update on costs “in the coming weeks.”That means patients paying through TrumpRx could end up paying far more than the administration’s advertised prices — especially if patients don’t stay on the lowest doses for long, Caplan said. Limited coverageAs part of the deal, Lilly and Novo Nordisk will charge Medicare and Medicaid $245 for a month’s supply of the shots, a move that will likely provide savings for the programs. Medicare enrollees will have their costs capped at $50 a month. Medicaid enrollees often don’t have copays.But not everyone on Medicare or Medicaid is eligible.Under the deal, Medicare will continue to cover the weight loss drugs for people who are overweight or obese and have another qualifying condition, such as heart or kidney disease. The agreement doesn’t expand coverage to people using the drugs for weight loss alone. Medicare, by law, is barred from covering weight loss drugs, Cubanski, of KFF, said.Eli Lilly CEO talks deal to cut medication prices with the Trump administration09:10The lack of expanded coverage is a significant omission, said Stacie Dusetzina, a health policy professor at Vanderbilt University in Nashville, Tennessee. Medicare is one of the largest payers in the country, and without broader coverage, millions of patients will remain priced out even as the administration touts lower costs.“You would have to change the law or go through several regulatory steps to be able to offer coverage outside of an already covered indication,” Dusetzina said. A White House spokesperson said the administration wanted to first lower prices for patients who would most benefit, such as those with risk factors associated with obesity. It’s possible the administration could eventually expand Medicare coverage through a pilot program. Ricks, the CEO of Lilly, said at a briefing Thursday that the government plans to launch one in spring 2026 that would be voluntary for Medicare plans. Still, there are issues Medicare plans would have to weigh, Dusetzina said. “The plans will have to think about how many more people might be interested in enrolling and using these drugs and how that would affect their costs,” she said. “So, again, it’s not totally clear to me how that will get operationalized and how soon Medicare beneficiaries would expect to see lower prices.”Ricks said the pilot would be “at no cost” to the plans.Dr. Shauna Levy, a specialist in obesity medicine and the medical director of the Tulane Weight Loss Center in New Orleans, said the deal is “a step in the right direction” but she worries if the administration is overstating the potential savings.“As an obesity community, I think we will remain skeptical of this deal until we see how it actually plays out,” Levy wrote in an email. Berkeley Lovelace Jr.Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved